72.20
+1.69%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Basilea Pharmaceutica AG Allschwil
Its shares trade on SIX under the ticker BSLN.SW. It has been listed since 25 March 2004. In the fiscal year to 31 December 2025, it reported revenue of CHF 232.4m and net income of CHF 40.2m. At that date it held total assets of CHF 282.0m and shareholders' equity of CHF 127.9m.
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt. The company went IPO on 2004-03-25. The firm focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The firm has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Mar 2004
- Employees
- 225
- Website
- basilea.com ↗
Leadership
Pay as last reported
- Mr. Domenico ScalaNon-Executive Independent Chairman of the Board, since 2011CHF 337,676
- Mr. David VeitchChief Executive Officer, Member of the Management CommitteeCHF 1.8m
- Dr. Thomas WernerNon-Executive Independent Vice Chairman of the Board, since 2011CHF 224,798
- Mr. Adesh KaulMember of the Management Committee, Chief Financial Officer
- Dr. Gerrit HauckMember of the Management Committee, Chief Technology Officer
- Dr. Laurenz KellenbergerMember of the Management Committee, Chief Scientific Officer
- Mr. Damian HellerGeneral Counsel, Corporate Secretary
- Mr. Peter BielmeierHead of Global Quality Management
- Mrs. Ursula EberhardtHead of Global Human Resources
- Mr. Raimond Grewenig-scheurichHead of Global Commercial
- Mr. Mark JonesHead of Global Affairs
- Dr. Marc EngelhardtMember of the Management Committee, Chief Medical Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 75
- Social
- 54
- Governance
- 73
- Women in the workforce
- 33%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Basilea Pharmaceutica AG has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, Basilea Pharmaceutica AG also faces certain weaknesses that need to be addressed:
Opportunities
- Basilea Pharmaceutica AG can capitalize on the following opportunities to enhance its growth and market position:
Threats
- Basilea Pharmaceutica AG should also be mindful of the following threats that could impact its business operations:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.